{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:51:26Z","timestamp":1793724686833,"version":"4.6.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic Spontaneous Urticaria (CSU) and Atopic Dermatitis (AD) are both immune-mediated inflammatory skin disorders that often co-exist with other atopic conditions such as asthma and allergic rhinitis. Their shared immunopathological pathways raise the question of a possible interrelationship.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the prevalence, clinical features, and immunological profiles of AD in patients with CSU and to explore implications for diagnosis and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>425 CSU patients treated in Northern Israel between 2021 and 2024, were retrospectively analyzed. Disease activity was assessed using the Urticaria Activity Score-7 (UAS7) and Investigators' Global Assessment (IGA) for AD. The prevalence of asthma, total serum IgE levels, and therapeutic responses were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 425 CSU patients, 42 (10%) were also diagnosed with AD. Co-morbid patients had a higher frequency of asthma (40%) and high total IgE levels (67%) compared to CSU-only patients. A substantial subset of co-morbid cases required biologic treatments with Dupilumab, offering benefit in AD-dominant cases unresponsive to Omalizumab. Severe CSU was more prevalent in the CSU\u2009+\u2009AD group (though the prevalence was not statistically significant).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CSU and AD frequently co-exist, likely due to overlapping T-cell\u2013mediated immunopathogenic mechanisms. High total IgE and asthma comorbidity may indicate an underlying AD component in CSU patients. Recognition of this overlap is essential for appropriate therapeutic decision-making, including potential escalation to biologic agents targeting T-cell cytokine pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2025.1681375","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:28:44Z","timestamp":1763965724000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Co-existence of chronic spontaneous urticaria with atopic dermatitis: clinical and immunological perspectives"],"prefix":"10.3389","volume":"6","author":[{"given":"Elias","family":"Toubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raeda","family":"Mubariki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahava","family":"Vadasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2500\/aap.2018.39.4114","article-title":"Association of alopecia areata with atopic dermatitis and chronic spontaneous urticaria","volume":"39","author":"Magen","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/ijd.14000","article-title":"Associations of chronic urticarial with atopic and autoimmune comorbidities: a nationwide population-based study","volume":"57","author":"Chiu","year":"2018","journal-title":"Int J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jaad.2019.02.034","article-title":"Characterization of chronic urticarial and associated conditions in a large population of adolescents","volume":"81","author":"Rosman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000525870","article-title":"Risk of atopic disorders in patients with chronic urticarial: a systematic review and met-analysis","volume":"239","author":"Zhang","year":"2023","journal-title":"Dermatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guidelines for the definition, classification, diagnosis, and management of urticarial","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/S0190-9622(03)02539-8","article-title":"Consensus conference on pediatric atopic dermatitis","volume":"49","author":"Eichenfield","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e17520","DOI":"10.1371\/journal.pone.0017520","article-title":"Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments. 1985\u20132010","volume":"6","author":"Rehal","year":"2011","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/jdv.14541","article-title":"Different expression patterns of plasma Th1, Th2, Th17 and Th22-related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria","volume":"32","author":"Chen","year":"2018","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-18187-z","article-title":"Increased serum IL-17, IL-31, IL-33 levels in chronic spontaneous urticaria","volume":"7","author":"Lin","year":"2017","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"879754","DOI":"10.3389\/fimmu.2022.879754","article-title":"The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jaci.2016.04.036","article-title":"Autoreactive T cells in chronic spontaneous urticaria target the IgE fc receptor I\u03b1 subunit","volume":"138","author":"Auyeung","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"102634","DOI":"10.1016\/j.jaut.2021.102634","article-title":"Autoreactive T cells and their role in atopic dermatitis","volume":"120","author":"De Bruyn Carlier","year":"2021","journal-title":"J Autoimmun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/cimb46040186","article-title":"Precision dermatology: a review of molecular biomarkers and personalized therapies","volume":"46","author":"Tan","year":"2024","journal-title":"Curr Issues Mol Biol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1681375\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:28:45Z","timestamp":1763965725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1681375\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":15,"alternative-id":["10.3389\/falgy.2025.1681375"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1681375","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"article-number":"1681375"}}